Remove Arcturus Remove Blogging Remove Technology
article thumbnail

Xconomy Q&A: An Update with Arcturus Therapeutics CEO Joseph Payne

Xconomy

Things have been moving quickly in recent weeks for the San Diego RNA drug developer Arcturus Therapeutics. After initiating a reverse merger last month, Arcturus signed a research collaboration and worldwide licensing agreement with Janssen Pharmaceuticals, part of the Johnson & Johnson (NYSE: JNJ ) family of companies.

article thumbnail

RNA Specialist Arcturus Therapeutics Gets $3M R&D Grant for CF Drug

Xconomy

San Diego-based Arcturus Therapeutics said today Cystic Fibrosis Foundation Therapeutics has agreed to provide $3 million to fund research and development of a new messenger RNA drug that could be broadly used to treat cystic fibrosis patients. Arcturus says its technology can be used to make.